JOHNSON JOHN 4

What Happened

• John Johnson, a director of Xeris Biopharma (XERS), sold 15,000 shares in an open-market transaction on June 4, 2026 for a weighted average price of $6.09, receiving $91,422. On the same day he was granted 24,193 restricted stock units (RSUs) (no cash cost) and 32,996 stock options (derivative grant) recorded with a value of $202,925 and a reported per-share price of $6.15.
• The sale is typically viewed as routine trading, while the RSUs and option grant are equity compensation awards tied to future vesting.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (timely).
• Sale: 15,000 shares disposed; weighted average sale price $6.09; total proceeds $91,422. (Footnote: shares sold across prices from $5.97 to $6.17; holder will provide detailed breakdown on request.)
• Grants: 24,193 RSUs (acquired at $0.00) and 32,996 stock options (derivative grant) shown with a value of $202,925 and price $6.15.
• Vesting/conditions: Both the RSUs and options vest in full upon the earlier of June 4, 2026 or the date of the company’s next annual meeting, subject to continued service. (See footnotes for details.)
• Rule 10b5-1 plan: The sale was made under a pre-established Rule 10b5-1 trading plan adopted by the reporting person on Aug 13, 2025.
• Shares owned after transaction: Not specified in the excerpt provided.

Context

• RSUs represent a contingent right to receive shares upon vesting; these are compensation awards and do not represent an immediate purchase or market bet. The option grant is a derivative award that will only deliver value if the stock exceeds the option terms upon exercise; the filing does not indicate any immediate exercise or sale of those option shares.
• The open-market sale being executed under a 10b5-1 plan suggests it was pre-scheduled rather than a discretionary trade made that day.